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Abstract
The polyomavirus family currently includes thirteen human polyomavirus (HPyV) species. In
immunocompromised and elderly persons HPyVs are known to cause disease, such as pro-
gressive multifocal leukoencephalopathy (JCPyV), haemorrhagic cystitis and nephropathy
(BKPyV), Merkel cell carcinoma (MCPyV), and trichodysplasia spinulosa (TSPyV). Some
recently discovered polyomaviruses are of still unknown prevalence and pathogenic poten-
tial. Because HPyVs infections persist and might be transferred by blood components to
immunocompromised patients, we studied the seroprevalence of fourteen polyomaviruses
in adult Dutch blood donors. For most polyomaviruses the observed seroprevalence was
high (60–100%), sometimes slightly increasing or decreasing with age. Seroreactivity
increased with age for JCPyV, HPyV6 and HPyV7 and decreased for BKPyV and TSPyV.
The most recently identified polyomaviruses HPyV12, NJPyV and LIPyV showed low overall
seroprevalence (~5%) and low seroreactivity, questioning their human tropism. Altogether,
HPyV infections are common in Dutch blood donors, with an average of nine polyomavi-
ruses per subject.
Introduction
The Polyomaviridae family comprises non-enveloped double-stranded DNA viruses that infect
a broad spectrum of hosts. After primary infection, usually in childhood, polyomaviruses
cause asymptomatic persistent infection accompanied by low-level replication and shedding,
for instance in urine [1,2]. Since 2007 the number of identified human polyomaviruses
(HPyVs) has greatly increased. They are currently grouped in thirteen species, including the
‘classic’ BK polyomavirus (BKPyV) and JC polyomavirus (JCPyV) [2,3]. A novel polyomavirus
called the Lyon IARC polyomavirus (LIPyV) that was identified in 2017 has not been assigned
to a polyomavirus species yet [4]. The major capsid protein VP1 forms the exterior of the viral
particle and is immunodominant [5]. Polyomaviruses do not cause disease in healthy hosts;
however, they can reactivate and cause disease in individuals who are immunocompromised.
BKPyV is the main cause of polyomavirus-associated nephropathy (PVAN) that occurs in
up to 10% of kidney transplant patients [6]. Haemorrhagic cystitis, also caused by BKPyV,







Citation: Kamminga S, van der Meijden E,
Feltkamp MCW, Zaaijer HL (2018) Seroprevalence
of fourteen human polyomaviruses determined in
blood donors. PLoS ONE 13(10): e0206273.
https://doi.org/10.1371/journal.pone.0206273
Editor: Efrem Lim, Arizona State University,
UNITED STATES
Received: May 30, 2018
Accepted: October 10, 2018
Published: October 23, 2018
Copyright: © 2018 Kamminga et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information
files.
Funding: This project was supported by Sanquin
Blood Supply Foundation, PPO 15-04 (https://
www.sanquin.org/research) to HLZ and MCWF.
The funder had no role in study design, data
collection and analysis, decision to publish, or
preparation of the manuscript.
Competing interests: The authors have declared
that no competing interests exist.
complicates between 6–30% of hematopoietic stem cell transplantations [7]. JCPyV causes
progressive multifocal leukoencephalopathy (PML), a potentially lethal, demyelinating brain
disease, which is found in HIV-infected AIDS patients, immunosuppressed transplantation
patients, and nowadays especially in multiple sclerosis (MS) patients treated with immuno-
modulatory drugs, such as natalizumab [8]. The incidence of PML in natalizumab-treated MS
patients can be as high as 20 per 1000 patients [9,10]. Merkel cell polyomavirus (MCPyV) is an
important cause of Merkel cell carcinoma (MCC). The incidence of MCC is low, approximately
0.4 per 100.000 person-years, though this appears to increase [11]. Less is known about the inci-
dence of diseases caused by other polyomaviruses, for example trichodysplasia spinulosa caused
by the trichodysplasia spinulosa polyomavirus (TSPyV) [2,12]. Karolinska Institute polyomavi-
rus (KIPyV) and Washington University polyomavirus (WUPyV) have been implicated in
respiratory disease [13–15], HPyV6 and HPyV7 in dyskeratotic dermatosis, and HPyV7 in thy-
momagenesis [16–19]. Furthermore, the New Jersey polyomavirus likely caused a unique but
severe case of vasculitis resulting in blindness, dermatitis and myositis. Altogether, the polyoma-
viruses are a significant cause of disease in the immunocompromised population.
Blood components (red blood cells, platelets and fresh frozen plasma) are administered to
haematological, transplant, and other immunocompromised patients in huge numbers. There-
fore, it is important to understand the epidemiology of polyomaviruses among healthy adults
and potential blood donors, including HPyVs that have been recognized just recently and of
which still very little is known. In this study the seroprevalence and seroreactivity were deter-
mined of fourteen polyomaviruses identified thus far in humans, in 1050 Dutch blood donors
subdivided into age categories. HPyV serology was performed using a custom bead-based
immunoassay which was recently validated for this purpose [20].
Materials and methods
Study population
The study population consisted of serum samples from 1050 Dutch blood donors. Donors
were included using weighted random selection from Dutch blood donations to obtain groups
of equal size in terms of age and sex. Serum samples from eighty blood donation centres were
collected over a period of two weeks to ensure an even geographic distribution over the Neth-
erlands (Fig 1). Every blood donation in the Netherlands is routinely screened for presence of
human immunodeficiency virus, hepatitis B and C virus and syphilis, only samples with a neg-
ative result were included in this study. Sex and age characteristics are summarized in Table 1.
The donors were divided in five age categories: 18–29, 30–39, 40–49, 50–59 and 60–69 years of
age. In total, 529 males and 521 females were included.
The study involves anonymous ’left over’ samples from blood donors who gave permission
to use this material for studies into blood-borne agents. Hence Sanquin’s scientific board, and
the secretary of Sanquin’s Ethical Advisory Board, decided that for this study permission from
the Ethical Advisory Board is not applicable.
Human polyomavirus multiplex immunoassay
A customized, recently described Luminex xMAP assay was used to measure IgG seroreactiv-
ity against the VP1 major capsid protein of BKPyV, JCPyV, KIPyV, WUPyV, MCPyV,
HPyV6, HPyV7, TSPyV, HPyV9, Malawi polyomavirus (MWPyV), Saint Louis polyomavirus
(STLPyV), HPyV12, NJPyV and LIPyV [20–22]. As described, each GST-VP1 fusion protein
was expressed in BL21 Rosetta bacteria and coupled to uniquely colored, glutathione-casein
cross-linked magnetic fluorescent polystyrene beads, which allows distinction between several
analytes in a single well.
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In the multiplex immunoassay the 1:100 diluted serum samples were incubated for one hour
in blocking buffer to suppress non-specific binding [22,23]. Biotinylated goat-α-human IgG
(H+L) (1:1000 Jackson ImmunoResearch Laboratories Inc., West Grove, PA, USA, catalogue
number: 109-065-088, antibody registry number: AB_2337628) followed by streptavidin-R-phy-
coerythrin (SAPE) (1:1000 Invitrogen, Waltham, MA, USA, catalogue number: S866) were used
to detect IgG responses against the individual VP1 antigens. A serially diluted mix of four
serum samples with known seroreactivity against various polyomaviruses was included in each
plate to measure intertest variability [20,21], which was low. Samples were then measured in a
Fig 1. Geographic distribution of blood donors. The geographic origin of 1050 collected serum samples in the
Netherlands is shown in a map by the location of the collection centres involved. Samples were collected over a period
of two weeks to ensure the inclusion of blood donation centres from all regions of the Netherlands. The number of
samples from each location is visualized by increasing circle size parallel to the number of samples from that location,
with a minimum of 1 and a maximum of 51 samples from individual centres. This image is used with permission from
Microsoft and was created using Microsoft Excel 2016.
https://doi.org/10.1371/journal.pone.0206273.g001
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Bio-Plex 100 analyzer (Bio-Rad Laboratories, Hercules, CA, USA) and analyzed using Bio-Plex
Manager 6.1 software (Bio-Rad Laboratories, Hercules, CA, USA). The intraclass correlation
coefficient for the 1:100 diluted controls was 0.91 (95% confidence interval: 0.81–0.97;
P<0.001). Specific seroreactivity was calculated by subtracting the median fluorescence inten-
sity (MFI) values of both a blank sample and of beads coupled to an irrelevant GST fusion pro-
tein, in this case GST-SV40 small T-antigen. Serum samples with a high response against
GST-SV40 small T-antigen (resulting in specific seroreactivity below or equal to minus 1000
MFI), were excluded for further analysis (n = 6). This is likely due to aspecific antigen binding,
although a genuine seroresponse against GST-SV40 small T-antigen cannot be excluded.
Determination of the cut-off value
For each HPyV a cut-off value for seropositivity was determined based on seroresponses of
Dutch children (n = 36) between 10 and 15 months old, as previously described [21], because
children of this age have lost maternal antibodies and have a low chance of being yet HPyV
exposed. To determine a seronegative population, a frequency distribution analysis with a bin
width of 250 MFI was performed and samples in bins with a frequency percentage above 10%
were used in the calculation of the cut-off score. The cut-off value is calculated by the mean
seroresponse of the seronegative population and adding three times the standard deviation.
This resulted in the following cut-off values, expressed as MFI, for BKPyV 391, JCPyV 349,
KIPyV 341, WUPyV 403, MCPyV 509, HPyV6 322, HPyV7 1069, TSPyV 346, HPyV9 446,
MWPyV 325, STLPyV 357, HPyV12 326, NJPyV 994, and LIPyV 438.
Statistical analysis
Statistical analysis was performed in IBM SPSS Statistics 23. Intraclass correlation coefficient
was calculated based on a single measures form, absolute-agreement and 2-way mixed-effects
model. Associations between categorical variables (e.g. sex, age categories) and seropositivity
were analysed by χ2 test (for trend) or Fisher’s exact test where appropriate. Mann-Whitney U
test was used to analyse differences in seropositivity numbers between the different age catego-
ries per donor. Seroreactivity was not normally distributed and was therefore analysed by a
non-parametric test, Jonckheere’s trend test for ordinal variables (in this case the association
between age and seroreactivity in seropositive samples).
Results
Human polyomavirus seroprevalence
In 1050 Dutch blood donors, the seroprevalence of each polyomavirus was determined by cal-
culating the proportion of serum samples with seroreactivity above the established MFI cut-off
Table 1. Demographics of study population.
Sex Total
Male Female
Age category 18–29 103 105 208
30–39 106 103 209
40–49 106 102 208
50–59 110 105 215
60–69 104 106 210
Total 529 521 1050
https://doi.org/10.1371/journal.pone.0206273.t001
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points. For the majority of polyomaviruses, the overall seropositivity was high, at least 60%
(Fig 2 and Table 2). However, for HPyV9 and especially for HPyV12, NJPyV and LIPyV the
overall seropositivity was low, 19.2%, 4.0%, 5.2% and 5.9% respectively. When the seropreva-
lences were analysed in relation to age, a significant positive association was observed for
KIPyV (χ2 test for trend: P<0.001), HPyV6 (P<0.001), HPyV7 (P<0.001) and TSPyV
(P = 0.04). For MCPyV, a negative association between seroprevalence and age was observed
(P = 0.013). Due to low numbers of seropositives, age comparisons were not performed for
HPyV12, NJPyV and LIPyV. For all HPyVs no significant differences in seropositivity were
observed related to sex.
All blood donors were seropositive for at least four polyomaviruses. The mean number of
infections per donor (± SD), based on seropositivity, was 8.7 ± 1.6 per subject (Fig 3). Partici-
pants in the lowest age category (18–29) had a mean of 8.2 ± 1.6 infections, which was signifi-
cantly lower (Mann-Whitney U test: P� 0.001) than the other age categories, which showed a
mean number of infections as follows: 30–39 years: 8.8 ± 1.7, 40–49 years: 8.7 ± 1.5, 50–59
years: 8.7 ± 1.5, and 60–69 years: 8.9 ± 1.6. No differences regarding the mean number of infec-
tions per donor were observed between the sexes.
Human polyomavirus seroreactivity
Seroreactivity detected in seropositive donors differed between the analysed HPyVs. The high-
est median MFI-values were measured for BKPyV (Fig 4). Intermediate values were measured
for KIPyV, WUPyV, MCPyV, HPyV6, HPyV7, TSPyV and MWPyV. Low to intermediate
median MFI values were measured for JCPyV, HPyV9 and STLPyV, although some highly
reactive serum samples were noted for HPyV9. The seroresponses against HPyV12, NJPyV
and LIPyV were generally very low.
Fig 2. Seroprevalence of indicated polyomaviruses in Dutch blood donors. The percentage seropositivity of each polyomavirus is shown for the donor age
categories 18–29 (checkers pattern, N = 206), 30–39 (solid white bars, N = 207), 40–49 (dots pattern, N = 207), 50–59 (light grey bars, N = 215) and 60–69 (diagonally
striped pattern, N = 209).
https://doi.org/10.1371/journal.pone.0206273.g002
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Seroreactivity was further analysed in relation to age by investigating potential trends
within the five age-categories shown in Fig 4. A significant age-dependent increase of seroreac-
tivity was observed for JCPyV, HPyV6 and HPyV7 (Jonckheere’s trend test: P<0.001, P<0.001
Table 2. Seropositivity numbers and seroprevalence.
Total Sex Age category
Polyomavirus type Male Female 18–29 30–39 40–49 50–59 60–69
(N = 1044a) (N = 527) (N = 517) (N = 206) (N = 207) (N = 207) (N = 215) (N = 209)
No. (%) No. (%) No. (%) No. (%) No. (%) No. (%) No. (%) No. (%)
BKPyV 1033 (98.9) 523 (99.2) 510 (98.6) 204 (99.0) 205 (99.0) 204 (98.6) 213 (99.1) 207 (99.0)
JCPyV 660 (63.2) 336 (63.8) 324 (62.7) 120 (58.3) 138 (66.7) 128 (61.8) 133 (61.9) 141 (67.5)
KIPyV�� 957 (91.6) 483 (91.7) 474 (91.7) 164 (79.6) 191 (92.3) 196 (94.7) 202 (94.0) 204 (97.6)
WUPyV 1033 (98.9) 521 (98.9) 512 (99.0) 204 (99.0) 204 (98.6) 205 (99.0) 213 (99.1) 207 (99.0)
MCPyV� 855 (81.9) 429 (81.4) 426 (82.4) 178 (86.4) 168 (81.2) 178 (86.0) 170 (79.1) 161 (77.0)
HPyV6�� 875 (83.8) 444 (84.3) 431 (83.4) 156 (75.7) 175 (84.5) 173 (83.6) 184 (85.6) 187 (89.5)
HPyV7�� 749 (71.7) 391 (74.2) 358 (69.2) 117 (56.8) 154 (74.4) 155 (74.9) 154 (71.6) 169 (80.9)
TSPyV� 831 (79.6) 431 (81.8) 400 (77.4) 156 (75.7) 160 (77.3) 163 (78.7) 183 (85.1) 169 (80.9)
HPyV9 200 (19.2) 91 (17.3) 109 (21.1) 44 (21.4) 43 (20.8) 40 (19.3) 36 (16.7) 37 (17.7)
MWPyV 1039 (99.5) 523 (99.2) 516 (99.8) 205 (99.5) 205 (99.0) 207 (100.0) 215 (100.0) 207 (99.0)
STLPyV 677 (64.8) 342 (64.9) 335(64.8) 118 (57.3) 145 (70.0) 139 (67.1) 143 (66.5) 132 (63.2)
HPyV12 42 (4.0) 15 (2.8) 27 (5.2) 11 (5.3) 10 (4.8) 5 (2.4) 4 (1.9) 12 (5.7)
NJPyV 54 (5.2) 22 (4.2) 32 (6.2) 8 (3.9) 4 (1.9) 4 (1.9) 16 (7.4) 22 (10.5)
LIPyV 62 (5.9) 33 (6.3) 29 (5.6) 10 (4.9) 14 (6.8) 10 (4.8) 14 (6.5) 14 (6.7)
a. 6 samples were excluded due to GST-SV40 small T reactivity.
� P < 0.05
�� P<0.001 χ2 test for trend for differences between age categories.
https://doi.org/10.1371/journal.pone.0206273.t002
Fig 3. Distribution of the cumulative number of polyomavirus infections per donor. The distribution of the
number of infecting polyomaviruses is shown among the tested blood donors, as indicated by seropositivity.
https://doi.org/10.1371/journal.pone.0206273.g003
Polyomavirus serology in blood donors
PLOS ONE | https://doi.org/10.1371/journal.pone.0206273 October 23, 2018 6 / 11
and P = 0.047, respectively). For HPyV9 a substantial increase was seen for the 60–69 age cate-
gory. In contrast, for BKPyV and TSPyV a significant decrease of seroreactivity was observed
in the higher age categories (Jonckheere’s trend test: P<0.001 for both viruses). No significant
trends were observed for the other HPyVs. The analyses were not performed for HPyV12,
NJPyV and LIPyV, due to low numbers of seropositives.
In general, no differences in seroreactivity between the sexes were observed, but for HPyV7
the overall median seroreactivity among seropositives was higher in men (9250 MFI in men
vs. 6464 MFI in women, Mann-Whitney U test: P = 0.018).
Discussion
In this study we determined the seroprevalence and seroreactivity of all currently known
human polyomaviruses in a large Dutch blood donor cohort. Our findings indicate that sero-
positivity for many polyomaviruses is common in this healthy population. At the same time,
for some recently identified HPyVs the seroprevalence was low.
With regard to most HPyVs that have been serologically analysed before, the seropreva-
lences reported here are in line with previous seroepidemiological studies in immunocompe-
tent populations from different continents [12,20,21,24–29], therefore we assume our findings
to be representative for most other immunocompetent populations. For KIPyV, HPyV6,
HPyV7 and TSPyV an increase in seroprevalence with higher age was noticed, which has also
been reported previously [21,24–27]. This could reflect continuous viral exposure throughout
life or frequent reactivation of persistent infection, which can boost HPyV seroresponses as
well [30]. Furthermore, we observed a decrease in seroprevalence with age for MCPyV, which
Fig 4. Seroreactivity in seropositive donors categorized by age. Box plots with whiskers represent 1-99th percentiles. Outliers are indicated by triangles. Age
categories shown are 18–29 (checkers pattern), 30–39 (solid white bars), 40–49 (dots pattern), 50–59 (light grey bars) and 60–69 (diagonally striped pattern). Only
MFI values from seropositive donors are shown. The total number of seropositives was for BKPyV: 1033; JCPyV: 660; KIPyV: 957; WUPyV: 1033; MCPyV: 855;
HPyV6: 875; HPyV7: 749; TSPyV: 831; HPyV9: 200; MWPyV: 1039; STLPyV: 677; HPyV12: 42; NJPyV: 54; LIPyV: 62.
https://doi.org/10.1371/journal.pone.0206273.g004
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was not published before to our knowledge, [21,24,25], and could represent a cohort effect.
HPyV infections with a stable seroprevalence in adult life are probably acquired during child-
hood, as previously indicated by a rapid increase in seropositivity during the first years of life
[21,25,31]. Due to the age restrictions on becoming a blood donor in the Netherlands, we did
not investigate the HPyV seroreactivity patterns in individuals under 18 years of age or older
than 69.
The seroreactivity of seropositive individuals differed with age between the HPyVs, with
decreasing intensity for BKPyV and TSPyV, increasing intensity for JCPyV, HPyV6 and
HPyV7, and stable intensity for KIPyV, WUPyV, MWPyV and STLPyV. Comparable trends
were obtained in healthy Australian, Czech and Italian populations [21,26,27,32,33], though
MCPyV seroreactivity did not increase with age in our cohort. The decrease in seroreactivity
for BKPyV and TSPyV suggests gradually less immunological boosting, possibly related to a
decrease in environmental exposure or diminished reactivation of these HPyVs, while the
increase in seroreactivity seen for JCPyV, HPyV6 and HPyV7 might reflect continuous expo-
sure or reactivation [30].
The serological profile of HPyV9 is unique compared to other polyomaviruses, with a small
subset of seropositive individuals that display very high seroreactivity in a background of weak
seroresponders. It was previously shown that HPyV9 has unique receptor binding properties,
and preferentially binds to a ligand which cannot be synthesized by humans, but can be
acquired through diet (red meat and milk) [34]. The necessity for a dietary ligand might
explain why this virus is less prevalent among humans than most other HPyVs. Whether
highly HPyV9-seroreactive subjects indeed ingest more dairy and meat-containing products
could be the subject of further study.
For HPyV12, NJPyV and LIPyV we detected a very low seroprevalence, approximately 5%,
with low seroreactivity for all three. In a pilot study, we obtained similar results and confirmed
the antigenicity of the used HPyV12- and NJPyV-VP1 antigens by specific polyclonal antibody
recognition [20]. Therefore, we believe the observed low seroprevalence of these polyomavi-
ruses to be genuine, and we consider the possibility that these polyomaviruses do not fre-
quently circulate in humans, and perhaps do not represent human polyomaviruses at all. For
HPyV12, this would fit with recent observations suggesting that HPyV12 represents a shrew
rather than a human polyomavirus [35]. For NJPyV it could very well be that the only pub-
lished patient was infected from an animal reservoir under exceptional circumstances, when
fleeing from flooding during hurricane Sandy [36]. LIPyV was identified in a skin swab sample
and subsequently detected in a small subset of oral fluids (2%), skin swabs (2%) and eyebrow
hair follicles (0.2%) [4]. In this case, the measured low seroprevalence might reflect the LIPyV
detection rate, though more studies are needed to further clarify the epidemiology of LIPyV.
In contrast to our data, a very recent study reported 90% seroprevalence for HPyV12, in an
Italian adult population [37]. This percentage is considerably higher than our finding and the
20% seroprevalence obtained previously for HPyV12 by Ehlers and co-workers using recombi-
nant VP1 and VP1-based VLP ELISA [35,38]. Since HPyV VP1-based and VLP based assays
generally obtain comparable results, as we have recently demonstrated for BKPyV [20], we
have no explanation thus far for this large discrepancy except differences in cut-off value deter-
mination and striking geographic differences in virus exposure. Suboptimal HPyV12 antigen
recognition, resulting from the use of a premature translation initiation site in HPyV12 VP1,
causing a 16 amino acids longer version of VP1 [39], was experimentally ruled out (S1 Fig).
Also for NJPyV a much higher seroprevalence was found in the Italian population (50%) than
in our population (5%) [37]. Overall, more (sero)epidemiological studies are needed to solve
these discrepancies and to define the natural host(s) of these viruses, for example by studying
seroprevalence in different geographic regions while using comparable serological methods.
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In conclusion, by analysing a large group of Dutch blood donors we showed that most
HPyV infections are common, although we found little indication of HPyV12, NJPyV and
LIPyV circulation in humans. Considering that blood donors are persistently infected with, on
average, nine different polyomaviruses and assuming that episodes of viremia sometimes
occur, the consequences for the safety of blood transfusion, especially for immunocompro-
mised recipients, remains to be established.
Supporting information
S1 Fig. HPyV12 seroreactivity. Based on VP1 sequence alignment, the translation initiation
site of the HPyV12-VP1 sequence may be located 48 nucleotides (16 amino acids) downstream
of the 5’ end of the VP1 open reading frame. In order to compare the antigenicity, both the
380 amino acids long version and the 364 amino acids long version of the HPyV12-VP1 pro-
tein were expressed and used to analyse a cohort of kidney transplant recipients (n = 65). The
seroreactivity measured with each protein was similar (Pearson R2 = 0.99).
(TIF)
S1 File. Dataset. Dataset containing population characteristics and immunoassay results.
(XLSX)
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